Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27918170 | 0.90 | GPBAR1 (0.63) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL4594713 | 0.89 | GPBAR1 (0.62) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL13734171 | 0.85 | GPBAR1 (0.58) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL2472816 | 0.84 | GPBAR1 (0.57) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL2473629 | 0.83 | KMT2A (0.51) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL1776068 | 0.83 | GPBAR1 (0.59) | GPBAR1GAATSHRALDH1A1GABRA5 | |
| SCHEMBL2320097 | 0.82 | GPBAR1 (0.47) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL2475844 | 0.82 | GPBAR1 (0.59) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL1574735 | 0.82 | KMT2A (0.73) | GPBAR1GAATSHRKMT2AMEN1 | |
| SCHEMBL2471731 | 0.81 | KMT2A (0.51) | GPBAR1GAATSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-1968973-A2 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007074078-A2 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | GABRA5, GABRA4, GABRA1 | GPBAR1 184/4885GAA 736/4885TSHR 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.